Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinomaA Harstrick, C H Köhne, W Hiddemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II studyU Klaassen, H Wilke, A Harstrick, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 30, 2010
Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolisD Díaz-Carballo, K Ueberla, V Kleff, et al.
British Journal of Cancer|May 10, 2012
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyD Strumberg, M E Scheulen, B Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2006
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?D Strumberg, A Awada, H Hirte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancerD Strumberg, S Brügge, M W Korn, et al.
Neurology|March 23, 2005
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worseningC C P Verstappen, S Koeppen, J J Heimans, et al.
British Journal of Cancer|May 29, 2008
Oxaliplatin-DNA adduct formation in white blood cells of cancer patientsA C Pieck, A Drescher, K G Wiesmann, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trialH Richly, B Schultheis, I A Adamietz, et al.
British Journal of Cancer|June 16, 2012
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative networkK Mross, C Dittrich, W E Aulitzky, et al.
Pageof 5